Bend Research Inc. has announced that it has entered into a licensing agreement with Eli Lilly and Company.
Under the terms of the agreement, Bend Research will make its proprietary spray-dried dispersion (SDD) technology available to Lilly.
This technology, which improves the bioavailability of compounds with low aqueous solubility, has been applied successfully to hundreds of compounds at various stages of development, from preclinical studies to Phase III clinical trials.
Lilly formulators and scientists will also have broad access to Bend Research’s portfolio of other drug-delivery technologies.
In addition, as part of an already existing agreement with Lilly, Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly to support its preclinical and clinical development programs.
“This expansion in our relationship with Lilly is a great milestone for us,” said Rod Ray, Chief Executive Officer of Bend Research.
Ray continued, “Our teams work well together and have a shared commitment to bring the best new medicines to caregivers and patients. We believe this collaboration will add significant value to Lilly’s research efforts and help them advance their compounds more quickly and efficiently.”